Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries.
High growth potential and slightly overvalued.
Share Price & News
How has Santhera Pharmaceuticals Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: S3F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: S3F underperformed the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: S3F underperformed the German Market which returned 17.1% over the past year.
Price Volatility Vs. Market
How volatile is Santhera Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Santhera Pharmaceuticals Holding undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: S3F (€13.64) is trading below our estimate of fair value (€1081.57)
Significantly Below Fair Value: S3F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: S3F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: S3F is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate S3F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: S3F is overvalued based on its PB Ratio (15.2x) compared to the DE Biotechs industry average (3.4x).
How is Santhera Pharmaceuticals Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: S3F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: S3F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: S3F's is expected to become profitable in the next 3 years.
Revenue vs Market: S3F's revenue (53.3% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: S3F's revenue (53.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if S3F's Return on Equity is forecast to be high in 3 years time
How has Santhera Pharmaceuticals Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: S3F is currently unprofitable.
Growing Profit Margin: S3F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: S3F is unprofitable, and losses have increased over the past 5 years at a rate of -46% per year.
Accelerating Growth: Unable to compare S3F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: S3F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: S3F has a negative Return on Equity (-580.67%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Santhera Pharmaceuticals Holding's financial position?
Financial Position Analysis
Short Term Liabilities: S3F's short term assets (CHF38.5M) exceed its short term liabilities (CHF27.2M).
Long Term Liabilities: S3F's short term assets (CHF38.5M) do not cover its long term liabilities (CHF69.6M).
Debt to Equity History and Analysis
Debt Level: S3F's debt to equity ratio (649.6%) is considered high.
Reducing Debt: Insufficient data to determine if S3F's debt to equity ratio has reduced over the past 5 years.
Inventory Level: S3F has a low level of unsold assets or inventory.
Debt Coverage by Assets: S3F's debt is not covered by short term assets (assets are 0.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: S3F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: S3F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -26.9% each year
What is Santhera Pharmaceuticals Holding's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate S3F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate S3F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if S3F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if S3F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of S3F's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Meier (57yo)
Dr. Thomas Meier, Ph.D., has been the Chief Executive Officer of Santhera Pharmaceuticals Holding AG since October 1, 2011 and also serves as its Head of Executive Management Team. Dr. Meier served as the ...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD972.85K) is above average for companies of similar size in the German market ($USD425.50K).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
|CEO, Head of Executive Management Team & Director||7.9yrs||CHF960.85k||0.71% CHF942.6k|
|CFO & EVP||4.2yrs||no data||no data|
|Executive VP||4.6yrs||no data||no data|
|Head of Business Development & Executive VP||0yrs||no data||no data|
|Executive VP||2.7yrs||CHF1.24m||no data|
Experienced Management: S3F's management team is considered experienced (4.4 years average tenure).
|CEO, Head of Executive Management Team & Director||7.9yrs||CHF960.85k||0.71% CHF942.6k|
|Vice Chairman||0yrs||CHF274.28k||0.34% CHF452.4k|
Experienced Board: S3F's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.6%.
Santhera Pharmaceuticals Holding AG's company bio, employee growth, exchange listings and data sources
- Name: Santhera Pharmaceuticals Holding AG
- Ticker: S3F
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF143.335m
- Listing Market Cap: CHF131.905m
- Shares outstanding: 11.11m
- Website: https://www.santhera.com
Number of Employees
- Santhera Pharmaceuticals Holding AG
- Hohenrainstrasse 24
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SANN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Nov 2006|
|S3F||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Nov 2006|
|SPHD.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Nov 2006|
|0QN1||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Nov 2006|
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. The company’s portfolio comprises clinical stage and marketed treatments for neuroophthalmologic, neuromuscular, and pulmonary diseases. Its pipeline product, idebenone, is in Phase III clinical stage for the treatment of Duchenne muscular dystrophy. The company commercializes idebenone under the Raxone name in 20 countries. Its pipeline also includes omigapil, an investigational drug with anti-apoptotic properties in development to address unmet medical needs for patients with congenital muscular dystrophy; and POL6014, a clinical stage selective inhibitor of human neutrophil elastase to treat cystic fibrosis and other lung diseases. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/09/25 21:18|
|End of Day Share Price||2019/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.